Safety of zafirlukast: Results of a postmarketing surveillance study on 7976 patients in England

Drug Safety

Volumn 30, Issue 5, 2007, Pages 419-429

  Twaites, Beverley R ^a   Wilton, Lynda V ^a,b   Shakir, Saad A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ZAFIRLUKAST;

ABDOMINAL PAIN; ADULT; AGED; AGGRESSION; AGITATION; ANGIONEUROTIC EDEMA; ANXIETY; ARTICLE; ASTHMA; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONFUSION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; EOSINOPHILIA; ERYTHEMA MULTIFORME; FACE EDEMA; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GENERAL PRACTICE; HEADACHE; HEART PALPITATION; HEARTBURN; HEPATITIS; HUMAN; IMMUNOPATHOLOGY; JAUNDICE; LASSITUDE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL ETHICS; MIGRAINE; NATIONAL HEALTH SERVICE; NAUSEA; PARESTHESIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QUESTIONNAIRE; RASH; SIDE EFFECT; SKIN DISEASE; UNITED KINGDOM; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VOMITING;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ASTHMA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; ENGLAND; FAMILY PRACTICE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; TOSYL COMPOUNDS;

EID: 34248345396     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730050-00005     Document Type: Article

References (42)

1. Hay DW. Pharmacology of leukotriene receptor antagonists. More than inhibitors of bronchoconstriction. Chest 1997; 111 Suppl. 2: 34-5S
2. Hay DWP, Torphy TJ, Undem BJ. Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci 1995; 16 (9): 304-9
3. Bisgaard H. Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. Allergy 2001; 56 Suppl. 66: 7-11
4. Dunn CJ, Goa KL. Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma. Drugs 2001; 61 (2): 285-315
5. Lynch KR, O'Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999; 399 (6738): 789-93
6. Lipworth BJ. The emerging role of leukotriene antagonists in asthma therapy. Chest 1999; 115 (2): 313-6
7. AstraZeneca UK Ltd. Accolate: summary of product characteristics, 2004
8. O'Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest 1997; 111 (2): 27S-34
9. Adkins JC, Brogden RN. Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma. Drugs 1998; 55 (1): 121-44
10. Garcia-Marcos L, Schuster A, Perez-Yarza EG. Benefit-risk assessment of antileukotrienes in the management of asthma. Drug Saf 2003; 26 (7): 483-518
11. Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet 2003; 361: 587-94
12. Josefson D. Asthma drug linked with Churg-Strauss syndrome. Br Med J 1997; 315: 330
13. Wechsler ME, Drazen JM. Zafirlukast and Churg-Strauss syndrome. Chest 1999; 116 (1): 266-7
14. Wechsler ME, Pauwels R, Drazen JM. Leukotriene modifiers and Churg-Strauss syndrome. Drug Saf 1999; 21 (4): 241-51
15. Shakir SAW. Prescription-event monitoring. In: Strom BL, editor. Pharmacepidemiology. 4th ed. Chichester: John Wiley & Sons, Ltd, 2005: 203-16
16. Shakir SAW. Causality and correlation in pharmacovigilance. In: Talbot JCC, Waller P, editors. Stephen's detection of new adverse drug reactions. 5th ed. Chichester: John Wiley, 2004: 329-45
17. International ethical guidelines for biomedical research involving human subjects. Geneva: CIOMS/WHO, 2002
18. Guidelines on the practice of ethical committees in medical research involving human subjects. London: Royal College of Physicians of London, 1996
19. Frequently asked questions (question 7). In: Confidentiality: protecting and providing information. London: General Medical Council, 2004
20. Key C, Layton D, Shakir S. Results of a postal survey of the reasons for the non-response of by doctors in a prescription event monitoring study of drug safety. Pharmacolepidemiol Drug Saf 2002; 11: 143-8
21. Pearlman DS, Lampl KL, Dowling PJ, et al. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. Clin Ther 2000; 22 (6): 732-47
22. Kemp JP. Recent advances in the management of asthma using leukotriene modifiers. Am J Respir Med 2003; 2 (2): 139-56
23. Palmer LJ, Silverman ES, Weiss ST, et al. Pharmacogenetics of asthma. Am J Respir Med 2002; 165 (7): 861-6
24. Reimers A, Pichler C, Helbling A, et al. Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Clin Exp Allergy 2002; 32 (12): 1763-8
25. Sovani MP, Whale CI, Tattersfield AE. A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease. Drug Saf 2004; 27 (10): 689-715
26. Katon WJ, Richardson R, Lozano P, et al. The relationship of asthma and anxiety disorders. Pscychosom Med 2004; 66 (3): 349-55
27. Medicines and Healthcare products Regulatory Agency [online]. Available at URL: http://www.mhra.gov.uk [Accessed 2005 Feb 4]
28. Montelukast and zafirlukast in asthma. Drug Ther Bull 1998; 36 (9): 65-8
29. Singulair 10mg tablets/4 and 5mg paedriatric tablets: summary of product characteristics. Merck Sharp & Dohme Ld, 2005
30. Churg A, Churg J. Steroids and Churg-Strauss syndrome. Lancet 1998; 352 (9121): 32-3
31. Churg J, Churg A. Zafirlukast and Churg-Strauss syndrome. JAMA 1998; 279 (24): 1949-50
32. Honsinger RW. Zafirlukast and Churg-Strauss syndrome [comment]. JAMA 1998; 279 (24): 1949
33. Katz RS, Papernik M. Zafirlukast and Churg-Strauss syndrome [comment]. JAMA 1998; 279 (24): 1949
34. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115 (4): 284-90
35. Knoell DL, Lucas J, Allen JN. Churg-Strauss syndrome associated with zafirlukast. Chest 1998; 114 (1): 332-4
36. Richeldi L, Rossi G, Ruggieri MP, et al. Churg-Strauss syndrome in a case of asthma. Allergy 2002; 57 (7): 647-8
37. Reinus JF, Persky S, Burkiewicz JS, et al. Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast. Ann Intern Med 2000; 133 (12): 964-8
38. Actis GC, Morgando A, Lagget M, et al. Zafirlukast-related hepatitis; report of a further case. J Hepatol 2001; 35: 539-41
39. Moles J, Primo J, Fernandez JM, et al. Acute hepatocellular injury associated with zafirlukast. J Hepatol 2001; 35: 541-2
40. Wooltorton E. Asthma drug zafirlukast (Accolate): serious hepatic events. CMAJ 2004; 170 (11): 1668
41. Katial RK, Stelzle RC, Bonner MW, et al. A drug interaction between zafirlukast and theophylline. Arch Intern Med 1998; 158 (15): 1713-5
42. Adams RJ, Wilson DH, Taylor AW, et al. Psychological factors and asthma quality of life: a population based study. Thorax 2004; 59 (11): 930-5